Human RAD50 deficiency: Confirmation of a distinctive phenotype.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
06 2020
Historique:
received: 24 11 2019
revised: 24 02 2020
accepted: 09 03 2020
pubmed: 27 3 2020
medline: 29 1 2021
entrez: 27 3 2020
Statut: ppublish

Résumé

DNA double-strand breaks (DSBs) are highly toxic DNA lesions that can lead to chromosomal instability, loss of genes and cancer. The MRE11/RAD50/NBN (MRN) complex is keystone involved in signaling processes inducing the repair of DSB by, for example, in activating pathways leading to homologous recombination repair and nonhomologous end joining. Additionally, the MRN complex also plays an important role in the maintenance of telomeres and can act as a stabilizer at replication forks. Mutations in NBN and MRE11 are associated with Nijmegen breakage syndrome (NBS) and ataxia telangiectasia (AT)-like disorder, respectively. So far, only one single patient with biallelic loss of function variants in RAD50 has been reported presenting with features classified as NBS-like disorder. Here, we report a long-term follow-up of an unrelated patient with facial dysmorphisms, microcephaly, skeletal features, and short stature who is homozygous for a novel variant in RAD50. We could show that this variant, c.2524G > A in exon 15 of the RAD50 gene, induces aberrant splicing of RAD50 mRNA mainly leading to premature protein truncation and thereby, most likely, to loss of RAD50 function. Using patient-derived primary fibroblasts, we could show abnormal radioresistant DNA synthesis confirming pathogenicity of the identified variant. Immunoblotting experiments showed strongly reduced protein levels of RAD50 in the patient-derived fibroblasts and provided evidence for a markedly reduced radiation-induced AT-mutated signaling. Comparison with the previously reported case and with patients presenting with NBS confirms that RAD50 mutations lead to a similar, but distinctive phenotype.

Identifiants

pubmed: 32212377
doi: 10.1002/ajmg.a.61570
pmc: PMC7318339
doi:

Substances chimiques

Cell Cycle Proteins 0
DNA-Binding Proteins 0
MRE11 protein, human 0
NBN protein, human 0
Nuclear Proteins 0
MRE11 Homologue Protein EC 3.1.-
Acid Anhydride Hydrolases EC 3.6.-
RAD50 protein, human EC 3.6.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1378-1386

Informations de copyright

© 2020 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc.

Références

Cold Spring Harb Perspect Biol. 2014 Aug 07;6(9):a016428
pubmed: 25104768
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7376-81
pubmed: 10377422
Mutat Res. 1981 Jan;80(1):221-6
pubmed: 7207484
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):855-61
pubmed: 15279770
FASEB J. 2014 Mar;28(3):1331-41
pubmed: 24344331
Cerebellum. 2013 Aug;12(4):596-9
pubmed: 23436002
EMBO J. 2006 Nov 29;25(23):5527-38
pubmed: 17082765
DNA Repair (Amst). 2010 Dec 10;9(12):1299-306
pubmed: 21035407
Hum Mutat. 2010 Sep;31(9):1059-68
pubmed: 20597108
Biomolecules. 2015 Oct 23;5(4):2877-902
pubmed: 26512707
DNA Repair (Amst). 2011 Mar 7;10(3):314-21
pubmed: 21227757
Orphanet J Rare Dis. 2016 Oct 7;11(1):137
pubmed: 27717373
Am J Med Genet. 1991 Jul 1;40(1):44-50
pubmed: 1887849
Cell. 1999 Dec 10;99(6):577-87
pubmed: 10612394
Front Immunol. 2017 Dec 04;8:1683
pubmed: 29255463
Environ Mol Mutagen. 2017 Jun;58(5):235-263
pubmed: 28485537
Hum Mol Genet. 2005 Jan 15;14(2):307-18
pubmed: 15574463
DNA Repair (Amst). 2014 Jul;19:169-75
pubmed: 24746645
Brain. 2019 Apr 1;142(4):867-884
pubmed: 30879067
Am J Med Genet A. 2020 Jun;182(6):1378-1386
pubmed: 32212377
Hum Mutat. 2019 Oct;40(10):1690-1699
pubmed: 31033087
Mol Cell. 2016 Dec 1;64(5):1010
pubmed: 27912094
Am J Hum Genet. 2009 May;84(5):605-16
pubmed: 19409520
Arch Dis Child. 2000 May;82(5):400-6
pubmed: 10799436
Nat Rev Mol Cell Biol. 2017 Sep;18(9):563-573
pubmed: 28655905
Nucleic Acids Res. 1997 Aug 1;25(15):2985-91
pubmed: 9224597
Curr Biol. 2001 Jan 23;11(2):105-9
pubmed: 11231126
J Clin Invest. 2015 Sep;125(9):3585-99
pubmed: 26280580
Am J Med Genet A. 2018 Feb;176(2):492-495
pubmed: 29226581
Nucleic Acids Res. 1999 May 15;27(10):2072-9
pubmed: 10219078
Am J Med Genet. 1995 Jul 3;57(3):462-71
pubmed: 7545870
Hum Mol Genet. 2004 Sep 15;13(18):2155-63
pubmed: 15269180

Auteurs

Aviël Ragamin (A)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Gökhan Yigit (G)

Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.

Kristine Bousset (K)

Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany.

Filippo Beleggia (F)

Clinic I of Internal Medicine, University Hospital Cologne, Cologne, Germany.

Frans W Verheijen (FW)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Marie-Claire Y de Wit (MY)

Department of Child Neurology, Sophia Children's Hospital, Erasmus MC University Medical Center, Rotterdam, Netherlands.
ENCORE Expertise Center for Neurodevelopmental Disorders, Rotterdam, The Netherlands.

Tim M Strom (TM)

Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
Institute of Human Genetics, Technische Universität München, Munich, Germany.

Thilo Dörk (T)

Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany.

Bernd Wollnik (B)

Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
Cluster of Excellence "Multiscale Bioimaging: From Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Göttingen, Germany.

Grazia M S Mancini (GMS)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
ENCORE Expertise Center for Neurodevelopmental Disorders, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH